All Posts
Editorial | Selective digestive decontamination – Pro
22 May, 2023 | 13:34h | UTCSelective digestive decontamination – Pro – Intensive Care Medicine (free for a limited period)
Commentary on Twitter
#SDD? One of few areas in critical care where large RCTs/SRs demonstrate consistent advantage, without evident side effects. Pivotal
📃 standardized formulation/protocols
📚 education
🧫 ABT stewardship + rigorous IPC strategies, monitoring ABTs use/AMR
🖇️ https://t.co/VOqudX6E6k pic.twitter.com/YN5DuXknDL— Intensive Care Medicine (@yourICM) May 21, 2023
Drug-induced abnormal involuntary movements: prevalence and treatment
22 May, 2023 | 13:30h | UTC
RCT | Superior progression-free survival with Venetoclax-based regimens in first-line CLL treatment
22 May, 2023 | 13:32h | UTCFirst-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL – The ASCO Post
Commentary on Twitter
Venetoclax with obinutuzumab or rituximab as first-line treatment for pts with CLL & coexisting conditions has resulted in a large percentage of pts with undetectable minimal residual disease & long progression-free survival.
Read the Research Summary: https://t.co/2i45QN55Hz
— NEJM (@NEJM) May 14, 2023
M-A | Inhaled nitrous oxide for painful procedures in children and youth
22 May, 2023 | 13:29h | UTC
ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy
22 May, 2023 | 13:27h | UTC
Stenotrophomonas Maltophilia: review and meta-analysis of treatment options
22 May, 2023 | 13:25h | UTC
New pharmacological agents and novel cardiovascular pharmacotherapy strategies
22 May, 2023 | 13:24h | UTC
Commentary on Twitter
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022: a focused review by the ESC Working Group on #Pharmacotherapy 💊 https://t.co/DZ6FTqYwxk @jpkaski #HF #AFib #diabetes #lipids #EHJPharmacotherapy @AgewallStefan @FeliceGragnano pic.twitter.com/1DTCewbyPv
— European Society of Cardiology Journals (@ESC_Journals) May 20, 2023
Epidemiology of bladder cancer in 2023: a systematic review of risk factors
22 May, 2023 | 13:23h | UTCEpidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology
Review | Sarcopenia and cardiovascular diseases
22 May, 2023 | 13:22h | UTCSarcopenia and Cardiovascular Diseases – Circulation
M-A | Limited evidence for safety and effectiveness of most antidepressants in chronic pain management
18 May, 2023 | 13:50h | UTC
RCT | Once-weekly insulin icodec shows non-inferiority to daily insulin glargine in type 2 diabetes patients
18 May, 2023 | 13:48h | UTCSwitching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
A humorous peek into HIV research papers: a quick guide
18 May, 2023 | 13:46h | UTCTypes of HIV Papers — A Quick Guide – HIV and Observations
Commentary on Twitter
In his latest HIV and ID Observations post, @PaulSaxMD presents a quick guide to the different types of HIV papers, comic style. https://t.co/RYW6MuubCd (H/T @xkcd) pic.twitter.com/Zlh7PJOh8o
— NEJM Journal Watch (@JWatch) May 16, 2023
M-A | Timing of symptomatic venous thromboembolism after surgery
18 May, 2023 | 13:45h | UTC
Review | Hereditary colorectal, gastric, and pancreatic cancer
18 May, 2023 | 13:43h | UTCHereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open
Commentary on Twitter
Have a🔎at our latest comprehensive review covering all u need to know📜about hereditary 🧬colorectal, gastric & pancreatic🦀! https://t.co/y1LL0DNRiy@Adductor @DrRABurkhart #SoMe4Surgery #StepUp4CRC #SurgEd #MedTwitter @BJSAcademy @BJSurgery @juliomayol @young_bjs Great read! pic.twitter.com/JmmOmMBydO
— BJS Open (@BjsOpen) May 11, 2023
Podcast | Dysphagia pearls
18 May, 2023 | 13:42h | UTC#395 Dysphagia with Dr. Diana Snyder – The Curbsiders
RCT | The addition of Quizartinib to chemotherapy improves overall survival vs placebo in FLT3-ITD-positive AML patients
18 May, 2023 | 13:40h | UTCQuizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Acute myeloid leukaemia (AML) is a genetically heterogeneous disease with poor clinical outcomes.
A new study assessed the effect of quizartinib on overall survival in patients with FLT3-ITD-positive newly diagnosed AML, in addition to chemotherapy. https://t.co/MGOoVF5QOa
— The Lancet (@TheLancet) April 27, 2023
RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma
18 May, 2023 | 13:38h | UTCCabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360
Commentary on Twitter
Clinical Pearls & Morning Reports: Cabozantinib in Renal-Cell Carcinoma. How did the addition of cabozantinib to nivolumab and ipilimumab affect outcomes in the trial by Choueiri et al.? https://t.co/x1FzWBiasr #MedEd #MedTwitter pic.twitter.com/w4sns1ifLG
— NEJM Resident 360 (@NEJMres360) May 16, 2023
Fluorescence-guided surgery: comprehensive review
18 May, 2023 | 13:34h | UTCFluorescence-guided surgery: comprehensive review – BJS Open
Commentary on Twitter
Find all you ever wanted to know about the current state of fluorescence-guided surgery 🟢🔬🔪in our latest comprehensive review by @BJSurgery editor @paulo_sutt et al. Absolutely worth reading!https://t.co/Tgrj4UvOzV@BJSAcademy @juliomayol @young_bjs #SoMe4Surgery #MedTwitter pic.twitter.com/ReArdO1LOs
— BJS Open (@BjsOpen) May 17, 2023
Phase 2 RCT | Ropeginterferon shows better results in hematocrit control vs phlebotomy alone in patients withr polycythemia vera
18 May, 2023 | 13:37h | UTCRopeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera – NEJM Evidence
Cohort Study | Patients with joint hypermobility at greater risk of second ACL injury post-surgery within a year of return to sport
18 May, 2023 | 13:33h | UTCRCT | ART intensification shows no benefit in treating HIV-associated neurocognitive impairment
18 May, 2023 | 13:31h | UTC
WHO advises not to use non-sugar sweeteners for weight control in newly released guideline
16 May, 2023 | 15:04h | UTCNews Release: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline – World Health Organization
WHO Guideline: Use of non-sugar sweeteners – World Health Organization
Meta-Analysis: Health effects of the use of non-sugar sweeteners – World Health Organization
Cluster RCT | Early detection and treatment bundle reduces postpartum hemorrhage complications
16 May, 2023 | 15:02h | UTCSummary: An international, cluster-randomized trial assessed the effectiveness of a multicomponent clinical intervention for postpartum hemorrhage in patients having vaginal delivery. The study involved 80 secondary-level hospitals across Kenya, Nigeria, South Africa, and Tanzania, with 210,132 patients. The intervention group utilized a calibrated blood-collection drape for early detection of postpartum hemorrhage and a first-response treatment bundle, while the control group received usual care.
The primary outcome measured was a composite of severe postpartum hemorrhage (blood loss ≥1000 ml), laparotomy for bleeding, or maternal death from bleeding. The results showed a significant reduction in primary-outcome events in the intervention group (1.6%) compared to the usual-care group (4.3%) with a risk ratio of 0.40 (95% CI, 0.32 to 0.50; P<0.001). Postpartum hemorrhage detection rates were 93.1% and 51.1% in the intervention and usual-care groups, respectively, and treatment bundle adherence was 91.2% and 19.4%, respectively.
These findings demonstrate that early detection of postpartum hemorrhage and the use of a bundled treatment approach can significantly reduce the risk of severe postpartum hemorrhage, laparotomy for bleeding, or death from bleeding among patients having vaginal delivery. The results have important implications for improving clinical practice and reducing postpartum hemorrhage complications globally.
Article: Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Lifesaving solution dramatically reduces severe bleeding after childbirth – World Health Organization
Commentary on Twitter
In a large, cluster-randomized trial involving patients with PPH after vaginal delivery, a multicomponent intervention lowered the risk of severe PPH, laparotomy for bleeding, or maternal death from bleeding. Full results of the E-MOTIVE trial: https://t.co/NjcE4Q1rxM#IMNHC2023
— NEJM (@NEJM) May 9, 2023
Evidence-based recommendations | Mid- to late-term follow-up of primary hip and knee arthroplasty
16 May, 2023 | 14:57h | UTC
Consensus Paper | The new timing in acute care surgery (new TACS) classification
16 May, 2023 | 14:56h | UTC